Filtering Out Use of DOACs in Hemodialysis

Annals of Pharmacotherapy

Volumn 51, Issue 6, 2017, Pages 511-513

  Dager, William E ^a   Lee, Jin A ^a  

^a Department of Pharmacy Services ^*  (United States)

Author keywords

anticoagulants; anticoagulation; dialysis; end stage renal disease; renal failure

Indexed keywords

ANTICOAGULANT AGENT; DIRECT ACTING ORAL ANTICOAGULANT; UNCLASSIFIED DRUG;

BLOOD FILTRATION; CHADS2 SCORE; CHRONIC KIDNEY FAILURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG USE; HEMODIALYSIS; HUMAN; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEVERE RENAL IMPAIRMENT; THROMBOCYTE DYSFUNCTION; VENOUS THROMBOEMBOLISM; HEMORRHAGE; PROCEDURES; RENAL INSUFFICIENCY; THROMBOSIS;

ANTICOAGULANTS; HEMORRHAGE; HUMANS; RENAL DIALYSIS; RENAL INSUFFICIENCY; THROMBOSIS;

EID: 85019019526     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028016689265     Document Type: Note

References (16)

1. Vaziri ND, Gonzales EC, Wang J, Said S., Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: effect of hemodialysis. Am J Kidney Dis. 1994;23:828-835.
2. Lutz J, Menke J, Sollinger D, Schinzel H, Thürmel K., Haemostasis in chronic kidney disease. Nephrol Dial Transplant. 2014;29:29-40.
3. Remuzzi G, Marchesi D, Livio M. Altered platelet and vascular prostaglandin-generation in patients with renal failure and prolonged bleeding times. Thromb Res. 1978;13:1007-1015.
4. Yoshida E, Fujimura Y, Ikeda Y. Impaired high-shear-stress-induced platelet aggregation in patients with chronic renal failure undergoing haemodialysis. Br J Haematol. 1995;89:861-867.
5. Shlipak MG, Fried LF, Crump C. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003;107:87-92.
6. Dager WE., Can enoxaparin be used safely in end-stage renal disease? Semin Dial. 2011;24:381-382.
7. Boehringer Ingelheim Pharmaceuticals. Pradaxa [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2014.
8. Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW., Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation. 2015;131:972-979.
9. Bristol-Myers Squibb Company. Eliquis [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2014.
10. Wang X, Tirucherai G, Marbury TC. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016;56:628-636.
11. Chang M, Yu Z, Shenker A. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol. 2016;56:637-645.
12. Kufel WD, Zayac AS, Lehmann DF, Miller CD., Clinical application and pharmacodynamic monitoring of apixaban in a patient with end-stage renal disease requiring chronic hemodialysis. Pharmacotherapy. 2016;36:166-171.
13. Gosselin R, Grant RP, Adcock DM., Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays. Int J Lab Hematol. 2016;38:505-513.
14. Sarratt SC, Nesbit R, Moye R. Evaluation of safety outcomes of apixaban compared to warfarin in patients with end-stage renal disease. Ann Pharmacother. 21 January 2017 doi:10.1177/1060028016688226. [Epub ahead of print].
15. Ansari N., Peritoneal dialysis in renal replacement therapy for patients with acute kidney injury. Int J Nephrol. 2011;2011:739-794.
16. College of American Pathologists: Coagulation special testing heparin assay. CAP, 2014.